New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
05:45 EDTMYGN, AETAetna BRCA testing policy bulletin not a change, says William Blair
William Blair says shares of Myriad Genetics (MYGN) dropped 2% Friday after Aetna (AET) issued a clinical policy bulletin update for BRCA testing that changed the word "Myriad" to "Laboratory." The firm believes the bulletin does not represent a change to the status quo since a number of labs now offer BRCA testing. William Blair keeps an Outperform rating on Myriad.
News For MYGN;AET From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
10:52 EDTMYGNLeerink's life science tools analyst holds an analyst/industry conference call
Subscribe for More Information
March 26, 2015
10:04 EDTMYGNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:07 EDTMYGNMyriad Genetics downgraded to Sell from Neutral at Goldman
Subscribe for More Information
March 25, 2015
07:38 EDTAETPrice targets raised for Managed Care Organizations at UBS
UBS raised its price targets on the Managed Care Organizations in their coverage universe. The firm cites increased volumes, a lack of new legislation, the potential for industry consolidation, and limited exposure to international markets that face a weak macro economic backdrop. UBS raised its price target on Aetna (AET) to $128 from $120, Anthem (ANTM) to $175 from $163, Cigna (CI) to $149 from $140 and United Health (UNH) to $135 from $131. UBS has a Buy rating on all four stocks.
March 20, 2015
08:18 EDTAETLeerink healthcare services analyst holds an analyst/industry conference call
Healthcare Services Analyst Gupte discusses Sustainable Growth Rate (SGR) and the proposed pay-fors and implications For Healthcare Services on an Analyst/Industry conference call to be held on March 20 at 11 am.
07:41 EDTMYGNAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
05:17 EDTMYGNMyriad EMPATHY-P clinical study results to be highlighted at annual congress
Myriad Genetics announced that results from the EMPATHY-P clinical study of Prolaris in patients newly diagnosed with prostate cancer will be highlighted at the 30th Annual Congress of the European Association of Urology. The EMPATHY-P study evaluated the Prolaris test on 525 patient biopsy samples to determine the aggressiveness of prostate cancer in these newly diagnosed patients from five European countries including: Italy, Germany, Spain, Switzerland and the UK. The patients' biopsy samples also were evaluated using standard clinical pathology methods, which were then compared to the Prolaris test results. The EMPATHY-P data showed, overall, that the Prolaris test found 42% of the European men evaluated had a risk profile that was either lower or higher than would be expected using clinical pathology. Interestingly, this finding is consistent with the previously published U.S. Prostate Biopsy Research study, which found 51% of U.S. patients had a risk profile that differed from clinical pathology.
March 19, 2015
10:02 EDTAETOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:20 EDTAETAetna upgraded at Sterne Agee
As noted earlier, Sterne Agee upgraded Aetna to Buy from Neutral. The firm says that the company is the best-positioned name within the large-cap health plan space , a defensive sector that has little exposure to Europe and reasonable growth prospects, according to the firm.
06:19 EDTAETAetna upgraded to Buy from Neutral at Sterne Agee
Subscribe for More Information
March 18, 2015
12:46 EDTAETAetna, HackensackAlliance ACO announce collaboration
Subscribe for More Information
March 17, 2015
09:00 EDTAETAetna management to meet with JPMorgan
Subscribe for More Information
07:18 EDTMYGNMyriad Genetics announces collaboration expansion with BioMarin
Myriad Genetics (MYGN) announced an expansion of the company's collaboration with BioMarin Pharmaceutical (BMRN). Under the expanded collaboration, BioMarin will use Myriad's myChoice HRD companion diagnostic test to prospectively identify patients with metastatic breast, ovarian and potentially other tumor types that may be sensitive to talazoparib. Financial terms were not disclosed.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use